ABL1 and precursor B-cell acute lymphoblastic leukemia: Although it cannot be proven that the benefit from 16 doses of rituximab in the GRAALL study could extend to those with lower levels of CD20-expressing blasts or those with BCR-ABL-positive disease, our data suggest there could be a benefit of adding rituximab to the treatment of all patients with B-cell acute lymphoblastic leukaemia, regardless of the proportion of blasts expressing CD20 or BCR-ABL1 status.